Olivera J Finn


PUBLICATIONS(Selected from over 150)


1. MUC1 Protein Expression in Tumor Cells Regulates Transcription of of Proinflammatory Cytokines by Forming a Complex with Nuclear Factor-κB p65 and Binding to Cytokine Promoters: IMPORTANCE OF EXTRACELLULAR DOMAIN.

Cascio S, Zhang L, Finn OJ. (2011).

J Biol Chem. 286(49):42248-56. PMID: 22021035


2. Tumor antigen epitopes interpreted by the immune system as self or abnormal-self differentially affect cancer vaccine responses.

Ryan, SO, Turner, MS, Garnepy, J., Finn, OJ.

Cancer Res. (2010); 70 (14):5788-96. PMID:PMC-2905500


3. Vaccine against MUC1 antigen expressed in inflammatory bowel disease and cancer lessens colonic inflammation and prevents progression to colitis-associated colon cancer              

Beatty, PL, Narayanan, S, Gariépy, J, Ranganathan, S, Finn, OJ.

Cancer. Prev. Res. 2010, 3(4): 438-46. PMID:PMC2853738


4. Healthy individuals have T-cell and antibody responses to the tumor antigen cyclin B1 that when elicited in mice protect from cancer.        

Vella LA, Yu M, Fuhrmann SR, El-Amine M, Epperson DE, Finn OJ.

Proc Natl Acad Sci U S A. 2009;106(33):14010-5,.PMID: 19666607


5. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research.

Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, Mellman I, Prindiville SA, Viner JL, Weiner LM, Matrisian LM.

Clin Cancer Res. 2009;15(17):5323-37. PMID: 19723653


6. Cancer immunology.          

Finn OJ. N Engl J Med. 2008;358(25):2704-15. PMID: 18565863


7. MCF7 Side population cells with characteristics of cancer stem/progenitor cells express the tumor antigen MUC1.         

Engelmann K, Shen H, Finn OJ.

Cancer Res. 2008; 68(7):2419-26. PMID: 18381450


8. A phase I/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors.

Lepisto, A., Moser, AJ, Zeh, H., Lee, K., Bartlett, D., McKolanis, JR, Geller, B., Schmotzer, A., Potter, D., Whiteside, T., Finn, OJ, Ramanathan, R.

Cancer Therapy, 2008; vol. 6(B); 955–964. PMCID: PMC2614325


9. Lack of effective MUC1 tumor antigen-specific immunity in MUC1-transgenic mice results from a Th/T regulatory cell imbalance that can be corrected by adoptive transfer of wild-type Th cells.

Turner MS, Cohen PA, Finn OJ.

J Immunol 2007; 178:2787-93. PMID: 17220329


10. Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer.               

Ramanathan RK, Lee KM, McKolanis J, Hitbold E, Schraut W, Moser AJ, Warnick E, Whiteside T, Osborne J, Kim H, Day R, Troetschel M, Finn OJ.

Cancer Immunol Immunother 2005; 54:254-64. PMID: 15372205